NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  R. Niranjan.  Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration , 2018, Neurochemistry International.

[3]  R. Melki.  Alpha-synuclein and the prion hypothesis in Parkinson's disease. , 2018, Revue neurologique.

[4]  K. Schroder,et al.  Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice , 2018, Science Translational Medicine.

[5]  B. Christensen,et al.  NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease , 2018, npj Parkinson's Disease.

[6]  Ming Lu,et al.  Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease , 2018, Journal of Neuroinflammation.

[7]  N. Chen,et al.  NLRP3 inflammasome activation in the thymus of MPTP-induced Parkinsonian mouse model. , 2018, Toxicology letters.

[8]  Xiao-Liang Liu,et al.  Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review). , 2018, International journal of molecular medicine.

[9]  N. Ghanem,et al.  “Till Death Do Us Part”: A Potential Irreversible Link Between Aberrant Cell Cycle Control and Neurodegeneration in the Adult Olfactory Bulb , 2018, Front. Neurosci..

[10]  N. Chen,et al.  A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the α-Synuclein–Related Inflammatory Response , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[11]  Li Wang,et al.  Editor’s Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  N. Chen,et al.  Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome , 2017, International immunopharmacology.

[13]  K. Ray Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[14]  K. Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[15]  R. Ortega,et al.  Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson’s disease brain , 2017, Acta Neuropathologica.

[16]  Rishi Pal,et al.  The potential role of neuroinflammation and transcription factors in Parkinson disease , 2017, Dialogues in clinical neuroscience.

[17]  D. Wesson,et al.  The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases , 2016, Neurobiology of Disease.

[18]  M. Srivastava,et al.  Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways. , 2016, International immunopharmacology.

[19]  R. Ransohoff.  How neuroinflammation contributes to neurodegeneration , 2016, Science.

[20]  N. Chen,et al.  Environment-contact administration of rotenone: A new rodent model of Parkinson’s disease , 2015, Behavioural Brain Research.

[21]  Jing Deng,et al.  NOS1-derived nitric oxide promotes NF-κB transcriptional activity through inhibition of suppressor of cytokine signaling-1 , 2015, The Journal of experimental medicine.

[22]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[23]  F. Shi,et al.  NALP3 inflammasome activation in protein misfolding diseases. , 2015, Life sciences.

[24]  R. Jaenisch,et al.  Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation , 2015, Nature Communications.

[25]  W. Oertel,et al.  A new dopaminergic nigro-olfactory projection , 2015, Acta Neuropathologica.

[26]  Jiahuai Han,et al.  Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. , 2015, Nature chemical biology.

[27]  Lei Liu,et al.  Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome , 2015, Cell.

[28]  C. Power,et al.  Inflammasomes in the CNS , 2014, Nature Reviews Neuroscience.

[29]  P. Brundin,et al.  Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice , 2013, Acta Neuropathologica.

[30]  N. H. Rod,et al.  Psychosocial risk factors, pre‐motor symptoms and first‐time hospitalization with Parkinson's disease: a prospective cohort study , 2013, European journal of neurology.

[31]  M. Luquin,et al.  Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys , 2013, Acta Neuropathologica.

[32]  M. Brucale,et al.  Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies , 2013, PloS one.

[33]  C. Olanow,et al.  Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? , 2013, Movement disorders : official journal of the Movement Disorder Society.

[34]  A. Lees,et al.  Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.

[35]  D. Golenbock,et al.  NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity , 2012, Cellular and Molecular Life Sciences.

[36]  G. Núñez,et al.  Sensing and reacting to microbes through the inflammasomes , 2012, Nature Immunology.

[37]  S. Masters,et al.  Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. , 2011, Trends in molecular medicine.

[38]  S. Hayley,et al.  Inflammatory Mechanisms of Neurodegeneration in Toxin-Based Models of Parkinson's Disease , 2010, Parkinson's disease.

[39]  J. Kordower,et al.  Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys , 2010, Neurobiology of Aging.

[40]  F. Martinon.  Signaling by ROS drives inflammasome activation , 2010, European journal of immunology.

[41]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[42]  A. Petrie,et al.  Regional differences in the severity of Lewy body pathology across the olfactory cortex , 2009, Neuroscience Letters.

[43]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[44]  K. Jellinger.  Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders , 2009, Acta Neuropathologica.

[45]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[46]  N. Bohnen,et al.  Diagnostic performance of clinical motor and non‐motor tests of Parkinson disease: a matched case–control study , 2008, European journal of neurology.

[47]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[48]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[49]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[50]  J. Bertin,et al.  PYPAF7, a Novel PYRIN-containing Apaf1-like Protein That Regulates Activation of NF-κB and Caspase-1-dependent Cytokine Processing* , 2002, The Journal of Biological Chemistry.

[51]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[52]  D. Schaid,et al.  Anxiety disorders and depressive disorders preceding Parkinson's disease: A case‐control study , 2000, Movement disorders : official journal of the Movement Disorder Society.

[53]  A. Bowie,et al.  The Interleukin-1 Receptor/toll-like Receptor Superfamily: Signal Generators for Pro-inflammatory Interleukins and Microbial Products , 2022 .

[54]  T. Roth,et al.  Waking up to sleep episodes in Parkinson's Disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[55]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[56]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[57]  W. Gibb,et al.  Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[58]  Roger Barker,et al.  Environmental toxins and Parkinson's disease , 1989, Trends in Neurosciences.

[59]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[60]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[61]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[62]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[63]  S. Akira,et al.  Toll-like receptors. , 2003, Annual review of immunology.

[64]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[65]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .